Epigenetic enhancement of adoptive T cell immunotherapy.

• Tác giả: Zhenyu Dai, Melody Smith
• Ngôn ngữ: eng
• Thông tin xuất bản: United States : Cancer cell , 2025
• Bộ sưu tập: NCBI
• ID: 695628

Tóm tắt

Isshiki et al. and Porazzi et al. report that inhibiting enhancer of zeste homolog 1 (EZH1) and EZH2 enhances chimeric antigen receptor (CAR)/T cell receptor (TCR)-based therapies by reprogramming tumors to be more immunogenic and improving T cell phenotype and demonstrate the efficacy of this combination in preclinical models across hematologic and solid cancers. Clinical trials are ongoing to evaluate its safety and therapeutic potential.